Geron Corporation (GERN)
Nasdaq · Healthcare · Biotechnology
$1.21+0.83%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $777M
- Forward P/E
- 30.3
- 52-week range
- $1.04 – $2.01
- 52-week change
- −6.20%
- EPS (trailing)
- −$0.11
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Net income
- −$83.5M
- Diluted EPS
- −$0.13
From the company’s annual report on SEC EDGAR.
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Headquarters: Foster City, United States · 258 employees · geron.com